What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?
Deng
Chao
C
Chen
Jiezhong
J
Hu
Changhua
C
Huang
Xu-Feng
XF
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D009765:Obesity / Q000139:chemically induced; D000077152:Olanzapine; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D015363:Quinolones / Q000494:pharmacology* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D001569:Benzodiazepines; D000068180:Aripiprazole; D000077152:Olanzapine